Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
Breast Cancer
About this trial
This is an interventional treatment trial for Breast Cancer focused on measuring stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven node-positive breast cancer Postmenopausal Last menstrual period more than 12 months before initial surgery OR Any age with prior bilateral oophorectomy OR Age 50 or over with prior hysterectomy without oophorectomy (unrelated to malignancy) No distant metastases Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age: See Disease Characteristics Sex: Female Menopausal status: See Disease Characteristics Performance status: WHO (ECOG) 0-1 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 OR Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin normal SGOT and SGPT no greater than 1.5 times normal Alkaline phosphatase no greater than 1.5 times normal Renal: Creatinine less than 1.5 times normal Cardiovascular: No history of significant angina, congestive heart failure, or myocardial infarction within the past year No clinically significant arrhythmias or uncontrolled hypertension LVEF normal by MUGA, LV gated scan, or echocardiogram Other: No other concurrent serious illness No other prior or concurrent malignancy except adequately treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics
Sites / Locations
- Charing Cross Hospital